The U.S. Food and Drug Administration (FDA) has approved sparsentan as the first treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease that often leads to kidney failure. The decision marks a significant milestone for patients with this condition, who previously had no approved therapies.
FSGS affects approximately 5-7 people per million annually, causing scarring in the kidney’s filtering units. Sparsentan, developed by Travere Therapeutics, is a dual endothelin and angiotensin receptor antagonist that showed promising results in clinical trials. Analysts note this approval could pave the way for more treatments targeting rare kidney diseases.
“This is a breakthrough for patients who have waited decades for an approved therapy,” said a nephrology specialist familiar with the drug’s development. The FDA’s decision was based on Phase 3 trial data showing sparsentan significantly reduced proteinuria, a key marker of kidney damage.
While the approval brings hope, some experts caution that long-term outcomes remain to be seen. The treatment carries a black box warning for hepatotoxicity and requires monthly liver function monitoring. Healthcare systems now face challenges in ensuring access to this specialized therapy for a small patient population.